Pfizer receives FDA negative response for Tafamidis NDA
Tafamidis is an oral experimental compound which is used to treat the patients who are suffering from Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). FDA said the NDA which was
Cheplapharm has entered a strategic partnership to take over a portfolio of 20 mature medicines, along with three manufacturing facilities globally, from Sanofi.